These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 31424909)

  • 1. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
    He H; Liu L; Morin EE; Liu M; Schwendeman A
    Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
    Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
    Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
    Jiang Y; Jiang Z; Wang M; Ma L
    Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer nanomedicines: so many papers and so few drugs!
    Venditto VJ; Szoka FC
    Adv Drug Deliv Rev; 2013 Jan; 65(1):80-8. PubMed ID: 23036224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
    Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
    Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer nanomedicine: a review of recent success in drug delivery.
    Tran S; DeGiovanni PJ; Piel B; Rai P
    Clin Transl Med; 2017 Dec; 6(1):44. PubMed ID: 29230567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiota and cancer: In vitro and in vivo models to evaluate nanomedicines.
    Ladaycia A; Loretz B; Passirani C; Lehr CM; Lepeltier E
    Adv Drug Deliv Rev; 2021 Mar; 170():44-70. PubMed ID: 33388279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
    Bertrand N; Wu J; Xu X; Kamaly N; Farokhzad OC
    Adv Drug Deliv Rev; 2014 Feb; 66():2-25. PubMed ID: 24270007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
    Tracey SR; Smyth P; Barelle CJ; Scott CJ
    Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum-based combination nanomedicines for cancer therapy.
    Li Y; Lin W
    Curr Opin Chem Biol; 2023 Jun; 74():102290. PubMed ID: 36989943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.
    Bobo D; Robinson KJ; Islam J; Thurecht KJ; Corrie SR
    Pharm Res; 2016 Oct; 33(10):2373-87. PubMed ID: 27299311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
    Kwon S; Ko H; You DG; Kataoka K; Park JH
    Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicine Tumor Targeting.
    Lammers T
    Adv Mater; 2024 Jun; 36(26):e2312169. PubMed ID: 38361435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.